Search Results - "Gathe, Joseph"

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1 by Wyles, David L, Ruane, Peter J, Sulkowski, Mark S, Dieterich, Douglas, Luetkemeyer, Anne, Morgan, Timothy R, Sherman, Kenneth E, Dretler, Robin, Fishbein, Dawn, Gathe, Joseph C, Henn, Sarah, Hinestrosa, Federico, Huynh, Charles, McDonald, Cheryl, Mills, Anthony, Overton, Edgar Turner, Ramgopal, Moti, Rashbaum, Bruce, Ray, Graham, Scarsella, Anthony, Yozviak, Joseph, McPhee, Fiona, Liu, Zhaohui, Hughes, Eric, Yin, Philip D, Noviello, Stephanie, Ackerman, Peter

“…Among patients coinfected with HIV-1 and HCV, a sustained HCV virologic response was reported in 97% of patients treated with 12 weeks of daclatasvir plus…”
Get full text

Efficacy, Pharmacokinetics, and Safety Over 48 Weeks With Ibalizumab-Based Therapy in Treatment-Experienced Adults Infected With HIV-1: A Phase 2a Study by Gathe, Joseph C., Hardwicke, Robin L., Garcia, Fernando, Weinheimer, Steven, Lewis, Stanley T., Cash, Robert Brandon

“…Ibalizumab, a humanized monoclonal antibody targeting CD4, blocks HIV-1 entry into cells and is the first Food and Drug Adminstration-approved long-acting…”
Get full text

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial by DeJesus, Edwin, Rockstroh, Jürgen K, MD, Henry, Keith, MD, Molina, Jean-Michel, MD, Gathe, Joseph, MD, Ramanathan, Srinivasan, PhD, Wei, Xuelian, PhD, Yale, Kitty, MSc, Szwarcberg, Javier, MD, White, Kirsten, Prof, Cheng, Andrew K, MD, Kearney, Brian P, Prof

“…Summary Background The HIV integrase strand transfer inhibitor elvitegravir (EVG) has been co-formulated with the CYP3A4 inhibitor cobicistat (COBI),…”
Get full text

Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients by Baril, Jean-Guy, Angel, Jonathan B, Gill, M John, Gathe, Joseph, Cahn, Pedro, van Wyk, Jean, Walmsley, Sharon

“…We reviewed the current literature regarding antiretroviral (ARV)-sparing therapy strategies to determine whether these novel regimens can be considered…”
Get full text

Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial by Arribas, Jose R, Dr, Pialoux, Gilles, Prof, Gathe, Joseph, MD, Di Perri, Giovanni, Prof, Reynes, Jacques, Prof, Tebas, Pablo, MD, Nguyen, Thai, MD, Ebrahimi, Ramin, MS, White, Kirsten, PhD, Piontkowsky, David, MD

“…Summary Background Patients with HIV on antiretroviral therapy might benefit from regimen simplification to reduce pill burden and dosing frequency. We aimed…”
Get full text

COVID-19 Coexisting With the Human Immunodeficiency Virus: A Case Report by Gamboa, Elizabeth, Duran, Melanie, Gathe, Jr, Joseph C, Surani, Salim, Varon, Joseph

“…The newly discovered severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has impacted the world dramatically, forcing the medical community to quickly…”
Get full text

SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients by GATHE, Joseph C, IVE, Prudence, WOOD, Robin, SCHÜRMANN, Dirk, BELLOS, Nicholaos C, DEJESUS, Edwin, GLADYSZ, Andrzej, GARRIS, Cindy, YEO, Jane

“…To compare the magnitude and durability of the antiviral response to fosamprenavir (FPV) plus ritonavir (RTV) once-daily (FPV/r QD) with nelfinavir twice-daily…”
Get full text

Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy by Shelburne, 3rd, Samuel A, Hamill, Richard J, Rodriguez-Barradas, Maria C, Greenberg, Stephen B, Atmar, Robert L, Musher, Daniel W, Gathe, Jr, Joseph C, Visnegarwala, Fehmida, Trautner, Barbara W

Get full text

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor–Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study by Mills, Anthony, Crofoot, Gordon, McDonald, Cheryl, Shalit, Peter, Flamm, Jason A, Gathe, Joseph, Scribner, Anita, Shamblaw, David, Saag, Michael, Cao, Huyen, Martin, Hal, Das, Moupali, Thomas, Anne, Liu, Hui C, Yan, Mingjin, Callebaut, Christian, Custodio, Joseph, Cheng, Andrew, McCallister, Scott

“…OBJECTIVES:To evaluate the safety and efficacy of the novel tenofovir prodrug, tenofovir alafenamide (TAF), as part of the first protease inhibitor–based…”
Get full text

Safety, Efficacy, and Pharmacokinetics of TBR-652, a CCR5/CCR2 Antagonist, in HIV-1–Infected, Treatment-Experienced, CCR5 Antagonist–Naive Subjects by Lalezari, Jacob, Gathe, Joseph, Brinson, Cynthia, Thompson, Melanie, Cohen, Calvin, Dejesus, Edwin, Galindez, Jorge, Ernst, Jerome A, Martin, David E, Palleja, Sandra M

“…OBJECTIVES:To determine the antiviral activity, pharmacokinetics, pharmacodynamics, safety, and tolerability of several dose levels of oral TBR-652 monotherapy…”
Get full text

A Once-Daily Lopinavir/Ritonavir-Based Regimen Provides Noninferior Antiviral Activity Compared With a Twice-Daily Regimen by Johnson, Margaret A, Gathe, Joseph C, Podzamczer, Daniel, Molina, Jean-Michel, Naylor, Christian T, Chiu, Yi-Lin, King, Martin S, Podsadecki, Thomas J, Hanna, George J, Brun, Scott C

“…OBJECTIVE:To evaluate the safety and noninferiority and to explore the efficacy of administration of once-daily versus twice-daily lopinavir/ritonavir (LPV/r)…”
Get full text

Fecal Transplantation for Clostridium Difficile—“All Stool May Not Be Created Equal” by Gathe, Joseph C., Diejomaoh, Efemena M., Mayberry, Carl C., Clemmons, John B.

“…Clostridium difficile is a gram-positive bacterium that is recognized as a causative organism of pseudomembranous enterocolitis. This infection has become a…”
Get full text

Risk factors for vitamin D deficiency in HIV-infected patients in the south central United States by Crutchley, Rustin D, Gathe, Jr, Joseph, Mayberry, Carl, Trieu, Angel, Abughosh, Susan, Garey, Kevin W

“…We evaluated the prevalence of serum 25-hydroxyvitamin D [25(OH)D] deficiency and the risk factors for vitamin D deficiency in HIV-infected patients in the…”
Get more information

Resolution of severe cryptosporidial diarrhea with rifaximin in patients with AIDS by Gathe, Jr, Joseph C, Mayberry, Carl, Clemmons, John, Nemecek, John

Get full text

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial by Eron, Joseph, Yeni, Patrick, Gathe, Joseph, Estrada, Vicente, DeJesus, Edwin, Staszewski, Schlomo, Lackey, Philip, Katlama, Christine, Young, Benjamin, Yau, Linda, Sutherland-Phillips, Denise, Wannamaker, Paul, Vavro, Cindy, Patel, Lisa, Yeo, Jane, Shaefer, Mark

“…Lopinavir-ritonavir is a preferred protease inhibitor co-formulation for initial HIV-1 treatment. Fosamprenavir-ritonavir has shown similar efficacy and safety…”
Get full text

Efficacy of the Protease Inhibitors Tipranavir plus Ritonavir in Treatment-Experienced Patients: 24-Week Analysis from the RESIST-1 Trial by Gathe, Joseph, Cooper, David A., Farthing, Charles, Jayaweera, Dushyantha, Norris, Dorece, Pierone, Gerald, Steinhart, Corklin R., Trottier, Benoit, Walmsley, Sharon L., Workman, Cassy, Mukwaya, Geoffrey, Kohlbrenner, Veronika, Dohnanyi, Catherine, McCallister, Scott, Mayers, Douglas

“…Background. Improved treatment options are needed for patients infected with multidrug-resistant human immunodeficiency virus type 1 (HIV-1). The nonpeptidic…”
Get full text

Fatal Relapse of Myelodysplastic Syndrome in a Patient with HIV/Hepatitis C Coinfection Treated with Simeprevir/Sofosbuvir by Diejomaoh, Efemena Michael, Gathe, Joseph Clayton, Mayberry, Carl Craig, Clemmons, John Benjamin, Miguel, Bernie, Glombicki, Alan, Daquioag, Benjamin

“…Registrational studies and observational cohorts clearly suggest sustained virologic response (SVR) rates in HIV-/hepatitis C–coinfected patients are similar…”
Get full text

Safety and Efficacy of Enfuvirtide in Combination with Darunavir-Ritonavir and an Optimized Background Regimen in Treatment-Experienced Human Immunodeficiency Virus-Infected Patients: the Below the Level of Quantification Study by DEJESUS, Edwin, GOTTLIEB, Michael S, GATHE, Joseph C, GREENBERG, Michael L, GUITTARI, Carol Jean, ZOLOPA, Andrew R

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients by Gathe, Jr, Joseph C, Pierone, Gerald, Piliero, Peter, Arasteh, Keikawus, Rubio, Rafael, Lalonde, Richard G, Cooper, David, Lazzarin, Adriano, Kohlbrenner, Veronika M, Dohnanyi, Catherine, Sabo, John, Mayers, Douglas

“…The efficacy, safety, and pharmacokinetics of three doses of tipranavir/ritonavir (TPV/r) in highly treatment-experienced human immunodeficiency virus…”
Get more information

Long-Term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: An uncontrolled, open-label, single-arm follow-on study by Gathe, Joseph C., Wood, Robin, Sanne, Ian, Dejesus, Edwin, Dirk, Schürmann, Gladysz, Andrzej, Garris, Cindy, Givens, Naomi, Elston, Robert, Yeo, Jane

“…Background: In the SOLO study (APV30002), once-daily antiretroviral treatment with the protease inhibitor fosamprenavir (FPV) 1400 mg boosted by ritonavir (r)…”
Get full text